• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.

作者信息

Bose Prithviraj, Verstovsek Srdan, Cortes Jorge E, Tse Susan, Gasior Yvonne, Jain Nitin, Jabbour Elias J, Estrov Zeev, Alvarado Yesid, DiNardo Courtney D, Pemmaraju Naveen, Kornblau Steven M, Kadia Tapan M, Daver Naval G, Naqvi Kiran, Short Nicholas J, Masarova Lucia, Villareal John, Pierce Sherry A, Nogueras-Gonzalez Graciela, Huang Xuelin, Garcia-Manero Guillermo, Kantarjian Hagop M, Ravandi Farhad

机构信息

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Leukemia. 2020 Sep;34(9):2489-2492. doi: 10.1038/s41375-020-0778-0. Epub 2020 Feb 25.

DOI:10.1038/s41375-020-0778-0
PMID:32099037
Abstract
摘要

相似文献

1
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.鲁索替尼与地西他滨治疗骨髓增殖性肿瘤后急性髓系白血病患者的1/2期研究。
Leukemia. 2020 Sep;34(9):2489-2492. doi: 10.1038/s41375-020-0778-0. Epub 2020 Feb 25.
2
Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.地西他滨和维奈克拉治疗异柠檬酸脱氢酶1/2突变的急性髓系白血病
Am J Hematol. 2021 May 1;96(5):E154-E157. doi: 10.1002/ajh.26122. Epub 2021 Feb 19.
3
The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.维奈托克和地西他滨用于治疗相关急性髓系白血病合并晚期非血液系统恶性肿瘤的可行性。
Leuk Res. 2019 Sep;84:106196. doi: 10.1016/j.leukres.2019.106196. Epub 2019 Jul 30.
4
Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study.在改良的白消安/环磷酰胺预处理方案中添加鲁索利替尼和地西他滨预防高危急性髓系白血病复发：前瞻性 2 期研究。
Ann Hematol. 2024 Nov;103(11):4707-4719. doi: 10.1007/s00277-024-05972-w. Epub 2024 Sep 7.
5
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.一项关于新型口服PLK1抑制剂奥万塞替布用于复发或难治性急性髓系白血病患者联合治疗的Ib期研究。
Clin Cancer Res. 2020 Dec 1;26(23):6132-6140. doi: 10.1158/1078-0432.CCR-20-2586. Epub 2020 Sep 30.
6
Successful Decitabine Treatment in Unfit, Elderly Patients with Acute Myeloid Leukemia following Chronic Myeloproliferative Neoplasm.地西他滨成功治疗不适合化疗的慢性骨髓增殖性肿瘤后急性髓系白血病老年患者
Acta Haematol. 2018;140(4):231-233. doi: 10.1159/000493880. Epub 2018 Nov 1.
7
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.联合鲁索替尼和地西他滨治疗加速期和急变期骨髓增生性肿瘤的安全性和疗效。
Blood Adv. 2018 Dec 26;2(24):3572-3580. doi: 10.1182/bloodadvances.2018019661.
8
Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.伏立诺他联合地西他滨治疗急性髓系白血病的 1 期剂量递增临床试验。
Int J Hematol. 2021 Jan;113(1):92-99. doi: 10.1007/s12185-020-02994-8. Epub 2020 Sep 20.
9
Venetoclax with decitabine or azacitidine for AML.维奈托克联合地西他滨或阿扎胞苷治疗急性髓系白血病
Lancet Oncol. 2018 Dec;19(12):e672. doi: 10.1016/S1470-2045(18)30824-6. Epub 2018 Nov 1.
10
Acute myeloid leukemia arising from polycythemia vera underwent reversion to chronic phase of myeloproliferative neoplasm status post chemotherapy: Biclonal myeloid neoplasms with genomic evidence of a common early hematopoietic progenitor.真性红细胞增多症继发的急性髓系白血病在化疗后逆转至骨髓增殖性肿瘤慢性期：具有共同早期造血祖细胞基因组证据的双克隆性骨髓肿瘤
Hematol Oncol. 2021 Apr;39(2):254-257. doi: 10.1002/hon.2824. Epub 2020 Nov 10.

引用本文的文献

1
Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study.单独使用阿扎胞苷或联合使用阿扎胞苷治疗不符合强化化疗或异基因造血细胞移植条件的加速期和急变期骨髓增殖性肿瘤患者的结局——一项FIM研究
Hemasphere. 2025 Sep 4;9(9):e70202. doi: 10.1002/hem3.70202. eCollection 2025 Sep.
2
Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A.染色体碎裂相关的21号染色体扩增通过可靶向的DYRK1A过表达调控向急变期骨髓增殖性肿瘤的转化。
Nat Genet. 2025 Jun;57(6):1478-1492. doi: 10.1038/s41588-025-02190-6. Epub 2025 Jun 9.
3

本文引用的文献

1
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.联合鲁索替尼和地西他滨治疗加速期和急变期骨髓增生性肿瘤的安全性和疗效。
Blood Adv. 2018 Dec 26;2(24):3572-3580. doi: 10.1182/bloodadvances.2018019661.
2
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.新诊断的老年急性髓系白血病患者中，地西他滨5天方案与10天方案治疗的比较：一项随机2期试验
Lancet Haematol. 2019 Jan;6(1):e29-e37. doi: 10.1016/S2352-3026(18)30182-0. Epub 2018 Dec 10.
3
How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms.
The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms.髓系癌症中表观遗传靶分子与疗法的演变格局：聚焦急性髓系白血病和骨髓增殖性肿瘤
Leukemia. 2025 May 15. doi: 10.1038/s41375-025-02639-x.
4
SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms.SOHO最新技术进展与后续问题 | 骨髓增殖性肿瘤管理中的挑战性病例
Clin Lymphoma Myeloma Leuk. 2025 Jul;25(7):484-493. doi: 10.1016/j.clml.2025.02.003. Epub 2025 Feb 16.
5
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm.奥拉帕尼在先前骨髓增殖性肿瘤引起的IDH1突变急性髓系白血病中显示出显著的临床活性。
Br J Haematol. 2025 Apr;206(4):1121-1128. doi: 10.1111/bjh.19944. Epub 2024 Dec 19.
6
Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia.骨髓增殖性肿瘤转化为急性髓系白血病的防治
Haematologica. 2025 Apr 1;110(4):828-839. doi: 10.3324/haematol.2023.283950. Epub 2024 Oct 24.
7
How I treat secondary acute myeloid leukemia.我如何治疗继发性急性髓系白血病。
Blood. 2025 Mar 20;145(12):1260-1272. doi: 10.1182/blood.2024024011.
8
Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study.在改良的白消安/环磷酰胺预处理方案中添加鲁索利替尼和地西他滨预防高危急性髓系白血病复发：前瞻性 2 期研究。
Ann Hematol. 2024 Nov;103(11):4707-4719. doi: 10.1007/s00277-024-05972-w. Epub 2024 Sep 7.
9
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.当代加速/急变期骨髓增殖性肿瘤患者的治疗方法和结局。
Blood Adv. 2024 Jul 9;8(13):3468-3477. doi: 10.1182/bloodadvances.2024012880.
10
Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients.对 165912 名美国患者的真实队列中的癌症治疗超适应证和超指南使用进行系统分析。
Cell Rep Med. 2024 Mar 19;5(3):101444. doi: 10.1016/j.xcrm.2024.101444. Epub 2024 Feb 29.
我如何治疗费城染色体阴性骨髓增殖性肿瘤的急变期。
Blood. 2018 Nov 29;132(22):2339-2350. doi: 10.1182/blood-2018-03-785907. Epub 2018 Oct 17.
4
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.CPX-351（阿糖胞苷和柔红霉素）脂质体注射液与常规阿糖胞苷联合柔红霉素治疗新诊断的老年继发性急性髓系白血病患者的比较。
J Clin Oncol. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017.77.6112. Epub 2018 Jul 19.
5
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.基于 BET 蛋白溴结构域抑制剂的联合用药对骨髓增殖性肿瘤继发急性髓系白血病细胞具有高度活性。
Leukemia. 2017 Mar;31(3):678-687. doi: 10.1038/leu.2016.260. Epub 2016 Sep 28.
6
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.真性红细胞增多症和原发性血小板增多症中的原始细胞转化和纤维化进展：发病率及危险因素的文献综述
Blood Cancer J. 2015 Nov 13;5(11):e366. doi: 10.1038/bcj.2015.95.
7
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.地西他滨（一种去甲基化药物）对处于加速期或急变期/急性髓系白血病期的高危原发性骨髓纤维化和骨髓增殖性肿瘤患者的治疗益处。
Leuk Res. 2015 Sep;39(9):950-6. doi: 10.1016/j.leukres.2015.06.001. Epub 2015 Jun 11.
8
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.骨髓增殖性肿瘤白血病转化的基因组和功能分析
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5401-10. doi: 10.1073/pnas.1407792111. Epub 2014 Dec 2.
9
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.用于评估临床试验中治疗骨髓增生性肿瘤伴原始细胞增多/转化型（MPN-BP）患者反应的标准：骨髓增生性肿瘤急性髓系白血病后联盟的正式建议。
Leuk Res. 2012 Dec;36(12):1500-4. doi: 10.1016/j.leukres.2012.08.013. Epub 2012 Aug 28.
10
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.JAK 激酶抑制剂芦可替尼治疗难治性白血病患者的 2 期研究，包括骨髓增生性肿瘤后急性髓系白血病。
Blood. 2012 May 17;119(20):4614-8. doi: 10.1182/blood-2011-12-400051. Epub 2012 Mar 15.